Structured evidence table for Boswellia Recovery Meta-Analysis, generated from 1 reusable source document in the Migaku knowledge base.
| topic | claim | evidence level | citation | source |
|---|---|---|---|---|
| Boswellia Recovery Meta-Analysis | 11 12 12 11 13 Current pharmacological treatments provide inconsistent long-term efficacy and are associated with significant side effects []. | 3 | Giglio Mariateresa (2025) | Efficacy and Safety of Acmella oleracea and Boswellia serrata Extract as Add-On Therapy for Chronic Low Back Pain: An Observational, Real-World Cohort Study |
| Boswellia Recovery Meta-Analysis | Non-steroidal anti-inflammatory drugs (NSAIDs), though effective for inflammation, offer limited relief in CLBP with neuropathic components and may be associated with gastrointestinal, cardiovascular, and renal complications with prolonged use []. | 3 | Giglio Mariateresa (2025) | Efficacy and Safety of Acmella oleracea and Boswellia serrata Extract as Add-On Therapy for Chronic Low Back Pain: An Observational, Real-World Cohort Study |
| Boswellia Recovery Meta-Analysis | Opioids, despite their widespread use, lack evidence for long-term effectiveness in CLBP and pose serious risks, including tolerance, dependence, addiction, and misuse, prompting recommendations for restricted use [,]. | 3 | Giglio Mariateresa (2025) | Efficacy and Safety of Acmella oleracea and Boswellia serrata Extract as Add-On Therapy for Chronic Low Back Pain: An Observational, Real-World Cohort Study |
| Boswellia Recovery Meta-Analysis | 1 2 3 4 5 6 7 8 9 2 10 Low back pain is a leading cause of disability worldwide, affecting approximately 619 million people globally in 2020, with projections indicating that this number could rise to 843 million by 2050 []. | 3 | Giglio Mariateresa (2025) | Efficacy and Safety of Acmella oleracea and Boswellia serrata Extract as Add-On Therapy for Chronic Low Back Pain: An Observational, Real-World Cohort Study |
Source documents